RESUMEN
Cannabis sativa has been used for recreational, therapeutic and other uses for thousands of years. The plant contains more than 120 C21 terpenophenolic constituents named phytocannabinoids. The Δ9-tetrahydrocannabinol type class of phytocannabinoids comprises the largest proportion of the phytocannabinoid content. Δ9-tetrahydrocannabinol was first discovered in 1971. This led to the discovery of the endocannabinoid system in mammals, including the cannabinoid receptors CB1 and CB2. Δ9-Tetrahydrocannabinol exerts its well-known psychotropic effects through the CB1 receptor but this effect of Δ9-tetrahydrocannabinol has limited the use of cannabis medicinally, despite the therapeutic benefits of this phytocannabinoid. This has driven research into other targets outside the endocannabinoid system and has also driven research into the other non-psychotropic phytocannabinoids present in cannabis. This chapter presents an overview of the molecular pharmacology of the seven most thoroughly investigated phytocannabinoids, namely Δ9-tetrahydrocannabinol, Δ9-tetrahydrocannabivarin, cannabinol, cannabidiol, cannabidivarin, cannabigerol, and cannabichromene. The targets of these phytocannabinoids are defined both within the endocannabinoid system and beyond. The pharmacological effect of each individual phytocannabinoid is important in the overall therapeutic and recreational effect of cannabis and slight structural differences can elicit diverse and competing physiological effects. The proportion of each phytocannabinoid can be influenced by various factors such as growing conditions and extraction methods. It is therefore important to investigate the pharmacology of these seven phytocannabinoids further, and characterise the large number of other phytocannabinoids in order to better understand their contributions to the therapeutic and recreational effects claimed for the whole cannabis plant and its extracts.
Asunto(s)
Cannabinoides/farmacología , Cannabis/química , Receptores de Cannabinoides/efectos de los fármacos , Anciano , Cannabinoides/química , HumanosRESUMEN
Scientific journals that are owned by a learned society, like the Journal of Neurochemistry (JNC), which is owned by the International Society for Neurochemistry (ISN), benefit the scientific community in that a large proportion of the income is returned to support the scientific mission of the Society. The income generated by the JNC enables the ISN to organize conferences as a platform for members and non-members alike to share their research, supporting researchers particularly in developing countries by travel grants and other funds, and promoting education in student schools. These direct benefits and initiatives for ISN members and non-members distinguish a society journal from pure commerce. However, the world of scholarly publishing is changing rapidly. Open access models have challenged the business model of traditional journal subscription and hence provided free access to publicly funded scientific research. In these models, the manuscript authors pay a publication cost after peer review and acceptance of the manuscript. Over the last decade, numerous new open access journals have been launched and traditional subscription journals have started to offer open access (hybrid journals). However, open access journals follow the general scheme that, of all participating parties, the publisher receives the highest financial benefit. The income is generated by researchers whose positions and research are mostly financed by taxpayers' or funders' money, and by reviewers and editors, who frequently are not reimbursed. Last but not least, the authors pay for the publication of their work after a rigorous and sometimes painful review process. JNC itself has an open access option, at a significantly reduced cost for Society members as an additional benefit. This article provides first-hand insights from two former Editors-in-Chief, Kunihiko Suzuki and Leslie Iversen, about the history of JNC's ownership and about the difficulties and battles fought along the way to its current success and reputation. Scientific journals that are owned by a learned society, like the Journal of Neurochemistry (JNC) which is owned by the International Society for Neurochemistry (ISN), benefit the scientific community in that a large proportion of the income is returned to support the scientific mission of the Society. The income generated by the JNC enables the ISN to organize conferences as a platform for members and non-members alike to share their research, supporting researchers particularly in developing countries by travel grants and other funds, and to promote education in student schools. These direct benefits and initiatives for ISN members and non-members distinguish a society journal from pure commerce. However, the world of scholarly publishing is changing rapidly. Open access models have challenged the business model of traditional journal subscription and hence provide free access to publicly funded scientific research. In these models, the manuscript authors pay a publication cost after peer review and acceptance of the manuscript. Over the last decade, numerous new open access journals have been launched and traditional subscription journals have started to offer open access (hybrid journals). However, open access journals pertain to the general scheme that, of all participating parties, the publisher receives the highest financial benefit. The income is generated by researchers whose positions and research are mostly financed by tax payers' or funders' money, reviewers and editors, who frequently are not reimbursed. Last but not least, the authors pay for the publication of their work after a rigorous and sometimes painful review process. JNC itself has an open access option, at a significantly reduced cost for Society members as an additional benefit. This article provides first-hand insights from a long-standing Editor-in-Chief, Kunihiko Suzuki, about the history of JNC's ownership and about difficulties and battles fought on the way to its current success and reputation today. This article is part of the 60th Anniversary special issue.
Asunto(s)
Políticas Editoriales , Neuroquímica/tendencias , Publicaciones Periódicas como Asunto/tendencias , Sociedades Científicas/tendencias , Humanos , Aprendizaje , Neuroquímica/métodos , Revisión por Pares/métodos , Revisión por Pares/tendencias , Edición/tendenciasRESUMEN
More than 200 novel psychoactive drugs have been reported in Europe, with 73 added in 2012 and additional compounds encountered every week in 2013. Many of these are "designer psychostimulants" which aim to mimic the subjective effects of amphetamines, cocaine or 3,4-methylenedioxymethylamphetamine (MDMA; "Ecstasy"). Several drugs are based on the beta-ketoamphetamine cathinone chemical structure, others include aminoindanes, aminotetralins, piperazines, amphetamine analogues and pipradrol derivatives. Although a detailed analysis of the pharmacology of these novel drugs is largely lacking, a number of scientific studies have been reported in 2011-2013 and these are reviewed. All of the novel psychostimulants activate monoamine systems in the brain - with differing dopamine (DA) v serotonin (5-HT) preferences. Those activating principally DA systems are amphetamine-like stimulants, such as naphyrone, desoxypipradrol, 3,4-methylenedioxypyrovalerone (MDPV), and benzylpiperazine while those preferentially activating 5-HT mechanisms are MDMA-like or cocaine-like stimulants, such as mephedrone, methylone and other substituted cathinones, aminoindanes, aminotetralins and piperazines. The ability of mephedrone and other novel psychostimulants to substitute for methylamphetamine or cocaine in drug discrimination tests in rats, and the ability of mephedrone to induce conditioned place preference and to sustain self-administration behaviour suggests that this and other cocaine/methylamphetamine-like drugs have dependence liability. This article is part of the Special Issue entitled 'CNS Stimulants'.
Asunto(s)
Estimulantes del Sistema Nervioso Central/farmacología , Drogas de Diseño/farmacología , Psicotrópicos/farmacología , Animales , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Estimulantes del Sistema Nervioso Central/química , Drogas de Diseño/química , Humanos , Psicotrópicos/químicaRESUMEN
Novel Psychoactive Drugs (NPD) can be sold without restriction and are often synthetic analogues of controlled drugs. The tryptamines are an important class of NPD as they bind to the various serotonin (5-HT) receptor subtypes and cause psychosis and hallucinations that can lead to injury or death through misadventure. Here we report on the structure elucidation and receptor binding profiles of two widely marketed tryptamine-derived NPDs, namely alpha-methyl-tryptamine and 5-methoxy-N,N-diallyl-tryptamine.
Asunto(s)
Compuestos Alílicos/química , Indoles/síntesis química , Propilaminas/síntesis química , Psicotrópicos/síntesis química , Triptaminas/química , Compuestos Alílicos/síntesis química , Compuestos Alílicos/metabolismo , Células HEK293 , Humanos , Indoles/química , Indoles/metabolismo , Espectroscopía de Resonancia Magnética , Conformación Molecular , Propilaminas/química , Propilaminas/metabolismo , Unión Proteica , Psicotrópicos/química , Psicotrópicos/metabolismo , Receptores de Serotonina/química , Receptores de Serotonina/metabolismo , Agonistas de Receptores de Serotonina/síntesis química , Agonistas de Receptores de Serotonina/química , Espectrofotometría Ultravioleta , Triptaminas/síntesis química , Triptaminas/metabolismoAsunto(s)
Neurociencias/historia , Animales , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Retratos como AsuntoRESUMEN
The discovery of dopamine as a neurotransmitter in brain by Arvid Carlsson approximately 50 years ago, and the subsequent insight provided by Paul Greengard into the cellular signalling mechanisms triggered by dopamine, gained these researchers the Nobel Prize for Medicine in 2000. Dopamine research has had a greater impact on the development of biological psychiatry and psychopharmacology than work on any other neurotransmitter. Neuropsychological views of the role of dopamine in the CNS have evolved from that of a simple reward signal to a more complex situation in which dopamine encodes the importance or 'salience' of events in the external world. Hypofunctional dopamine states underlie Parkinson's disease and attention deficit hyperactivity disorder, and there is increasing evidence for dopamine hyperactivity in schizophrenia. Some of the medicines that are most widely used in psychiatry, such as L-DOPA, methylphenidate and neuroleptic drugs, act on dopaminergic mechanisms.
Asunto(s)
Encéfalo/fisiología , Dopamina/fisiología , Animales , Humanos , Neuronas/metabolismoRESUMEN
The synaptic actions of most neurotransmitters are inactivated by reuptake into the nerve terminals from which they are released, or by uptake into adjacent cells. A family of more than 20 transporter proteins is involved. In addition to the plasma membrane transporters, vesicular transporters in the membranes of neurotransmitter storage vesicles are responsible for maintaining vesicle stores and facilitating exocytotic neurotransmitter release. The cell membrane monoamine transporters are important targets for CNS drugs. The transporters for noradrenaline and serotonin are key targets for antidepressant drugs. Both noradrenaline-selective and serotonin-selective reuptake inhibitors are effective against major depression and a range of other psychiatric illnesses. As the newer drugs are safer in overdose than the first-generation tricyclic antidepressants, their use has greatly expanded. The dopamine transporter (DAT) is a key target for amphetamine and methylphenidate, used in the treatment of attention deficit hyperactivity disorder. Psychostimulant drugs of abuse (amphetamines and cocaine) also target DAT. The amino-acid neurotransmitters are inactivated by other families of neurotransmitter transporters, mainly located on astrocytes and other non-neural cells. Although there are many different transporters involved (four for GABA; two for glycine/D-serine; five for L-glutamate), pharmacology is less well developed in this area. So far, only one new amino-acid transporter-related drug has become available: the GABA uptake inhibitor tiagabine as a novel antiepileptic agent.
Asunto(s)
Fármacos del Sistema Nervioso Central/farmacología , Proteínas de Transporte de Neurotransmisores/fisiología , Sistemas de Transporte de Aminoácidos/fisiología , Animales , Antidepresivos/farmacología , Antidepresivos/uso terapéutico , Humanos , Psicofarmacología , Sinapsis/efectos de los fármacos , Sinapsis/fisiología , Proteínas de Transporte Vesicular de Monoaminas/antagonistas & inhibidores , Proteínas de Transporte Vesicular de Monoaminas/fisiologíaRESUMEN
Julie Axelrod was a laboratory technician until the age of 42, when he finally achieved his PhD and independence. He worked at the National Institutes of Health for most of his career. Among his early pioneering research achievements in applying chemical and biochemical approaches to neuroscience were the discoveries of the painkiller acetaminophen (Tylenol, Paracetamol) and the liver microsomal drug-metabolizing enzymes, and the establishment of catechol-O-methyltransferase as an important enzyme in catecholamine metabolism. He shared the Nobel Prize in Physiology or Medicine in 1970 for his discovery that the reuptake of noradrenaline (norepinephrine) into the nerve endings from which it was released represented a novel method of neurotransmitter inactivation. An important corollary was the finding that antidepressant drugs acted as inhibitors of this uptake process. Subsequent work in his laboratory on the control of melatonin biosynthesis in the pineal gland provided new insights into the way in which the nervous system controls circadian rhythms, and offered an early model system in which to study the rapid control of mammalian gene expression. Axelrod continued actively in research until shortly before his death, and trained many students who have gone on to become leaders of the new field of biochemical neuropharmacology.
Asunto(s)
Acetaminofén/historia , National Institutes of Health (U.S.) , Premio Nobel , Norepinefrina , Acetaminofén/farmacocinética , Historia del Siglo XX , Historia del Siglo XXI , Melatonina/historia , Melatonina/farmacocinética , National Institutes of Health (U.S.)/historia , Norepinefrina/historia , Norepinefrina/metabolismo , Norepinefrina/farmacocinética , Norepinefrina/fisiología , Glándula Pineal/fisiología , Investigación/historia , Estados UnidosRESUMEN
The long-term use of cannabis, particularly at high intake levels, is associated with several adverse psychosocial features, including lower educational achievement and, in some instances, psychiatric illness. There is little evidence, however, that long-term cannabis use causes permanent cognitive impairment, nor is there is any clear cause and effect relationship to explain the psychosocial associations. There are some physical health risks, particularly the possibility of damage to the airways in cannabis smokers. Overall, by comparison with other drugs used mainly for 'recreational' purposes, cannabis could be rated to be a relatively safe drug.
Asunto(s)
Cannabinoides/efectos adversos , Trastornos del Conocimiento/inducido químicamente , Adolescente , Adulto , Animales , Estudios de Casos y Controles , Humanos , Pruebas NeuropsicológicasRESUMEN
Following the recognition of GABA as an inhibitory neurotransmitter, the discovery of high affinity GABA uptake, and the characterisation of GABA receptors great progress has been made in developing GABA pharmacology. Tiagabide, the first marketed GABA uptake inhibitor may be followed by new and more selective uptake inhibitors. Knowledge of the molecular pharmacology of GABA-A receptors, both synaptic and non-synaptic, may lead to improved anti-anxiety/anticonvulsant agents devoid of the sedative and dependence liabilities of earlier compounds and new hypnotics. Gaboxadol (THIP) is an example of a novel hypnotic that acts on GABA-A receptors by a non-benzodiazepine mechanism. Exploiting neurosteroid interactions with GABAergic mechanisms also holds much future promise.
Asunto(s)
Receptores de GABA-A/metabolismo , Ácido gamma-Aminobutírico/metabolismo , Animales , Benzodiazepinas/farmacología , Humanos , Receptores de GABA-A/efectos de los fármacosRESUMEN
The active compound in herbal cannabis, Delta(9)-tetrahydrocannabinol, exerts all of its known central effects through the CB(1) cannabinoid receptor. Research on cannabinoid mechanisms has been facilitated by the availability of selective antagonists acting at CB(1) receptors and the generation of CB(1) receptor knockout mice. Particularly important classes of neurons that express high levels of CB(1) receptors are GABAergic interneurons in hippocampus, amygdala and cerebral cortex, which also contain the neuropeptides cholecystokinin. Activation of CB(1) receptors leads to inhibition of the release of amino acid and monoamine neurotransmitters. The lipid derivatives anandamide and 2-arachidonylglycerol act as endogenous ligands for CB(1) receptors (endocannabinoids). They may act as retrograde synaptic mediators of the phenomena of depolarization-induced suppression of inhibition or excitation in hippocampus and cerebellum. Central effects of cannabinoids include disruption of psychomotor behaviour, short-term memory impairment, intoxication, stimulation of appetite, antinociceptive actions (particularly against pain of neuropathic origin) and anti-emetic effects. Although there are signs of mild cognitive impairment in chronic cannabis users there is little evidence that such impairments are irreversible, or that they are accompanied by drug-induced neuropathology. A proportion of regular users of cannabis develop tolerance and dependence on the drug. Some studies have linked chronic use of cannabis with an increased risk of psychiatric illness, but there is little evidence for any causal link. The potential medical applications of cannabis in the treatment of painful muscle spasms and other symptoms of multiple sclerosis are currently being tested in clinical trials. Medicines based on drugs that enhance the function of endocannabinoids may offer novel therapeutic approaches in the future.
Asunto(s)
Encéfalo/efectos de los fármacos , Cannabinoides/farmacología , Cannabis , Animales , Encéfalo/metabolismo , Moduladores de Receptores de Cannabinoides , Cannabinoides/uso terapéutico , Humanos , Abuso de Marihuana/complicaciones , Abuso de Marihuana/fisiopatología , Trastornos Mentales/inducido químicamente , Ratones , Fitoterapia/métodos , Receptores de Cannabinoides , Receptores de Droga/metabolismoRESUMEN
BACKGROUND/AIMS: It has been suggested that processing variants of gastrin, such as glycine-extended gastrin (G17-Gly), are enterotrophic to the colon. METHODS: Cell proliferation and crypt branching were studied in total parenteral nutrition (TPN) and orally fed rats after infusion of G17-Gly or gastrin-17. RESULTS: Gastrin produced an increase in the weight of the stomach and small intestine and a marked proliferative action on the proximal small intestine, which diminished distally. No proliferative effects of gastrin were seen in the colon. G17-Gly was associated with a small, but significant, increase in colonic weight but had little effect on cell proliferation, except in the gastric fundus. In the distal colon, G17-Gly was associated with a significant decrease in proliferation. Neither agent affected crypt branching in the small intestine or colon, but both proliferation and branching were significantly decreased by TPN. CONCLUSION: Gastrin was trophic to the stomach and the proximal small intestine but not the colon. G17-Gly had only modest proliferative actions on the intestinal epithelium in this study.
Asunto(s)
División Celular/efectos de los fármacos , Gastrinas/farmacología , Hormonas/farmacología , Nutrición Parenteral Total , Animales , Colon/efectos de los fármacos , Concentración de Iones de Hidrógeno , Mucosa Intestinal/efectos de los fármacos , Intestino Delgado/efectos de los fármacos , Masculino , Ratas , Ratas Wistar , Estómago/efectos de los fármacosAsunto(s)
Amiloidosis/tratamiento farmacológico , Amiloidosis/metabolismo , Componente Amiloide P Sérico/antagonistas & inhibidores , Componente Amiloide P Sérico/química , Amiloidosis/sangre , Animales , Reactivos de Enlaces Cruzados/química , Reactivos de Enlaces Cruzados/metabolismo , Reactivos de Enlaces Cruzados/farmacología , Reactivos de Enlaces Cruzados/uso terapéutico , Cristalografía por Rayos X , Humanos , Ratones , Modelos Moleculares , Unión Proteica/efectos de los fármacos , Estructura Cuaternaria de Proteína/efectos de los fármacos , Componente Amiloide P Sérico/metabolismoRESUMEN
Research on the therapeutic potential of cannabinoids has grown dramatically over the past few years. Recent advances include evidence that cannabinoid agonists are antihyperalgesic and antiallodynic in models of neuropathic pain. Development of novel cannabinoid agonists and cannabinoid preparations that are antinociceptive has important implications for the therapeutic use of this class of drugs.